McKesson (NYSE:MCK) had its price objective increased by Morgan Stanley from $168.00 to $182.00 in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock.
MCK has been the subject of a number of other reports. Robert W. Baird raised McKesson from a neutral rating to an outperform rating and raised their price objective for the stock from $164.00 to $197.00 in a research report on Friday, February 7th. UBS Group downgraded McKesson to a sell rating and set a $147.00 price objective for the company. in a research report on Thursday, January 9th. Barclays reissued a hold rating and set a $170.00 price objective on shares of McKesson in a research report on Sunday, January 19th. Deutsche Bank raised their price objective on McKesson from $153.00 to $173.00 and gave the stock a hold rating in a research report on Wednesday, February 5th. Finally, TheStreet downgraded McKesson from a b rating to a c- rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $162.80.
Shares of MCK opened at $168.03 on Tuesday. McKesson has a 52-week low of $110.52 and a 52-week high of $169.67. The company has a market capitalization of $29.73 billion, a PE ratio of -34.36, a price-to-earnings-growth ratio of 1.56 and a beta of 1.16. The stock has a fifty day simple moving average of $148.49 and a two-hundred day simple moving average of $143.71. The company has a quick ratio of 0.56, a current ratio of 0.98 and a debt-to-equity ratio of 1.33.
McKesson (NYSE:MCK) last issued its earnings results on Tuesday, February 4th. The company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.56 by $0.25. McKesson had a positive return on equity of 36.40% and a negative net margin of 0.41%. The business had revenue of $59.17 billion during the quarter, compared to the consensus estimate of $59.10 billion. During the same period last year, the company earned $3.40 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities analysts anticipate that McKesson will post 14.73 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Friday, February 28th. McKesson’s payout ratio is 12.09%.
In related news, CEO Brian S. Tyler sold 4,062 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $153.68, for a total transaction of $624,248.16. Following the completion of the sale, the chief executive officer now directly owns 16,254 shares of the company’s stock, valued at approximately $2,497,914.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.88% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new position in McKesson during the 3rd quarter valued at about $27,000. Usca Ria LLC purchased a new position in shares of McKesson in the 3rd quarter valued at about $27,000. Prime Capital Investment Advisors LLC purchased a new position in shares of McKesson in the 3rd quarter valued at about $27,000. Penserra Capital Management LLC boosted its stake in shares of McKesson by 55.6% in the 4th quarter. Penserra Capital Management LLC now owns 210 shares of the company’s stock valued at $30,000 after buying an additional 75 shares during the period. Finally, Keebeck Wealth Management LLC purchased a new position in shares of McKesson in the 4th quarter valued at about $29,000. Institutional investors own 87.09% of the company’s stock.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Further Reading: Asset Allocation, Balancing Your Investments
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.